Pentetreotide
Based on 1 Customer Validation
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with 111In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis.
For research use only. We do not sell to patients.
- Purity: 98.13%
- CAS No.: 138661-02-6
- Formula: C63H87N13O19S2
- Molecular Weight:1394.57
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Peptide Library
HY-L105
-
Cyclic Peptide Library
HY-L110
-
Nuclear Receptor Compound Library
HY-L126
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
|
RDC Peptide |
Neuroendocrine tumors have an increased number of somatostatin receptors, as compared to normal tissues. At present time, there are five known subtypes. Somatostatin receptor scintigraphy with 111In-Pentetreotide binds to two of these subtypes and is effective in visualizing neuroendocrine tumors, and its metastasis with an overall diagnostic sensitivity of 70% to 90%. It is considerably more sensitive than conventional anatomic imaging. Its usage in neuroendocrine tumors not only includes assessment of disease extent, but also in identified primary lesion, assesses treatment response, and selection for radionuclide therapy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 138661-02-6
-
Appearance Solid
-
Molecular Weight 1394.57
-
Formula C63H87N13O19S2
-
Color White to off-white
-
Sequence
DTPA-{d-Phe}-Cys-Phe-{d-Trp}-Lys-Thr-Cys-{Threoninol} (Disulfide bridge:Cys3-Cys8)
-
Sequence Shortening
DTPA-{d-Phe}-CF-{d-Trp}-KTC-{Threoninol} (Disulfide bridge:Cys3-Cys8)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (71.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Al-Suqri B. 111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors. Oman Med J. 2014 Sep;29(5):362-4. [Content Brief]
[2]. Masuda R, et al. Concise site-specific synthesis of DTPA-peptide conjugates: application to imaging probes for the chemokine receptor CXCR4. Bioorg Med Chem. 2011 May 15;19(10):3216-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7171 mL | 3.5853 mL | 7.1707 mL | 17.9267 mL |
| 5 mM | 0.1434 mL | 0.7171 mL | 1.4341 mL | 3.5853 mL | |
| 10 mM | 0.0717 mL | 0.3585 mL | 0.7171 mL | 1.7927 mL | |
| 15 mM | 0.0478 mL | 0.2390 mL | 0.4780 mL | 1.1951 mL | |
| 20 mM | 0.0359 mL | 0.1793 mL | 0.3585 mL | 0.8963 mL | |
| 25 mM | 0.0287 mL | 0.1434 mL | 0.2868 mL | 0.7171 mL | |
| 30 mM | 0.0239 mL | 0.1195 mL | 0.2390 mL | 0.5976 mL | |
| 40 mM | 0.0179 mL | 0.0896 mL | 0.1793 mL | 0.4482 mL | |
| 50 mM | 0.0143 mL | 0.0717 mL | 0.1434 mL | 0.3585 mL | |
| 60 mM | 0.0120 mL | 0.0598 mL | 0.1195 mL | 0.2988 mL |
Powered by Bioz